Login to Your Account



Eleven Reveals Early Success in EBI-005 Dry Eye Program

By Catherine Shaffer
Staff Writer

Friday, June 28, 2013

Eleven Biotherapeutics Inc., of Cambridge, Mass., is celebrating successful completion of its Phase Ib/IIa study of EBI-005 in dry eye disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription